NEW YORK, Aug. 5 (GenomeWeb News) - Caliper Life Sciences today reported a 222 percent gain in second-quarter revenues, driven by sales from Zymark, which the firm acquired in July 2003.
Caliper had revenues of $18.9 million in the quarter, up from $5.9 million in the second quarter of 2003.
The Hopkinton, Mass.-based firm posted a net loss of $9.5 million, or $.33 per share, compared to a net loss of $9.5 million, or $.38 per share, in the comparable period last year. This year's second-quarter results include a $2.4 million restructuring charge related to future lease costs of facilities no longer occupied following consolidation of its
Caliper finished the quarter with $52.9 million in cash, equivalents and short-term marketable securities.